Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

TEVIMBRA

TISLELIZUMAB-JSGR

Standard Dose
100MG/10ML(10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TEVIMBRA is listed in Drugs@FDA under application 761417 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TISLELIZUMAB-JSGR Form and strength INJECTABLE;INTRAVENOUS - 100MG/10ML(10MG/ML) Sponsor BEIGENE Submission history Latest submission status date: 2024-12-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview TEVIMBRA is listed in Drugs@FDA under application 761417 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TISLELIZUMAB-JSGR Form and strength INJECTABLE;INTRAVENOUS - 100MG/10ML(10MG/ML) Sponsor BEIGENE Submission history Latest submission status date: 2024-12-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.